Hyaluronidase Injection, 150 USP U/mL, 1mL Single-Dose Vial (4/Box)

NDC: 18657-117-04

Hyaluronidase (Human Recombinant) Injection, 150 USP Units/mL, 1 mL Single-Dose Vial (4/Box), Hylenex® — Halozyme

Indications and Usage

An adjuvant indicated to increase the dispersion and absorption of other injected drugs — including for ophthalmic use in peribulbar and retrobulbar block — as well as to achieve subcutaneous hydration and to improve resorption of contrast media in subcutaneous urography.

Dosage and Administration

To enhance dispersion and absorption of injected drugs, inject 50 to 300 units (most typically 150 units) prior to drug administration, or add the same amount directly to the injection solution. Not for intravenous use, as the enzyme is rapidly inactivated.

Warnings and Precautions

• Do not inject into or around an infected or acutely inflamed area, due to risk of spreading localized infection
• Not for topical use; should not be applied directly to the cornea
• Incompatible with furosemide, benzodiazepines, and phenytoin; should not be used to enhance dispersion of dopamine or alpha agonists
• When combined with local anesthetics, hastens onset but shortens duration and may increase the incidence of systemic reactions

Contraindications

Contraindicated in patients with known hypersensitivity to hyaluronidase or any excipient in the formulation.

Adverse Reactions

Most frequently reported reactions are mild local injection site effects such as erythema, swelling, and pain. Allergic reactions (urticaria, angioedema) and, rarely, anaphylactic-like reactions following retrobulbar block or intravenous injection have been reported.

Storage and Handling

Store unopened in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Discard unused portion.

How Supplied

Sterile, clear, colorless, nonpreserved solution in a 1 mL single-dose vial, 4 vials per box.

Professional use only. Clinical information summarized from FDA-approved prescribing information (Structured Product Labeling); refer to the full prescribing information via DailyMed for complete details.

If you have any questions related to DSCSA compliance, transaction history, regulatory data or quality assurance, please contact our team at compliance@dryeyerescue.com for more information.